Drug Name

Glucotrol XL (Glipizide)

Pharmacological action

Oral hypoglycemic agent, sulfonylurea derivative of II generation. Stimulates insulin secretion by pancreatic β-cells, increases insulin release. Increases the sensitivity of peripheral tissues to insulin. It has hypolipidemic, fibrinolytic effect, inhibits platelet aggregation.

Pharmacokinetics

After oral administration glipizide is quickly and completely absorbed from the gastrointestinal tract.

Binding with plasma proteins (mainly with albumin) is 98-99%.

It is metabolized in the liver. Less than 10% is excreted with urine and feces unchanged, about 90% is excreted with urine (80%) and with feces (10%) as metabolites.

Contraindications to use

Diabetes mellitus type 1 (insulin-dependent), ketoacidosis, precoma, coma, liver failure, renal failure (including patients on hemodialysis), pregnancy, breast-feeding, children and adolescents under 18 years, hypersensitivity to glimepiride, other sulfonylurea derivatives and sulfonamides.

Administration during pregnancy and lactation

Pregnancy and breast-feeding are contraindicated.

Use in children

Contraindicated for use in children and adolescents under 18 years of age.

Indications of the active substance Glucotrol XL (Glipizide)

Type 2 diabetes mellitus (insulin-independent) in patients with excess or normal body weight when diet therapy is ineffective.

Dosing regimen

It is established individually, depending on the clinical picture of the disease. Initial dose is 2.5-5 mg 1 time per day 15-30 minutes before breakfast. If necessary, the dose may be gradually (at intervals) increased by 2.5-5 mg/day. Daily doses over 15 mg should be divided into two doses.

Maximum doses: single - 15 mg, daily - 40 mg.